Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Epion Therapeutics logo — A clinical-stage company developing a minimally-invasive tre...

Epion Therapeutics

A clinical-stage company developing a minimally-invasive treatment for keratoconus

Founded 2012 United States Burlington, United States 12 employees Series A Total: $32.00M Biotechnology, Health Care +3

General Information

Company Name Epion Therapeutics
Founded Year 2012
Location United States Burlington, United States
Employees 12
Industries Biotechnology, Health Care, Health and Wellness +2
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Epion Therapeutics. To contact Epion Therapeutics, visit epiontx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Epion Therapeutics compare?

A PDF of Epion Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Epion Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Epion Therapeutics

Epion Therapeutics is a biotechnology startup based in the United States, founded in 2012. The company is focused on developing innovative treatments for corneal diseases, with the specific aim of addressing keratoconus, a common type of corneal ectasia. Epion's flagship product, EpiSmart, is a transformative cross-linking system designed to be minimally invasive, reducing discomfort and significantly cutting down recovery time compared to existing standards of care. Epion's approach is distinguished by its potential to treat both eyes simultaneously, eliminating the need for further deterioration. Notably, the company's last investment amounted to $32.00M, secured in a Series A round on September 30, 2022. The funding was provided by the Global Health Investment Fund (GHIF), underscoring investor confidence in Epion's vision-preserving solutions. With an elegant epi-on approach that avoids disrupting the epithelium, Epion is poised to enhance the standard of care, offering safer and more accessible treatments to millions of patients globally. By addressing a critical unmet need in eye care, Epion Therapeutics presents an attractive opportunity for venture capital investors seeking to support disruptive solutions in the pharmaceutical and healthcare industries.

Business keywords: clinical-stage company, corneal diseases, keratoconus, minimally-invasive treatment, EpiSmart, cross-linking system, epithelium, vision care, medical innovation, early intervention, ophthalmology, corneal ectasia, Michael W. Belin, vision preservation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $32.00M 1
Global Health Investment Fund (GHIF)
30 Sep 2022

Epion Therapeutics Alternatives & Competitors

View All Alternatives
Epion Therapeutics vs
Avedro
Avedro

Advancing the science of corneal cross-linking and non-invasive refractive correction for healthier...

Series F
Health Care, Medical Devices
Epion Therapeutics vs
iVeena
iVeena United States

Lead programs comprise of novel proprietary eye drops; IVMED-80 (granted ODD) for keratoconus, and I...

Venture round
6 employees
Biotechnology, Life Sciences
Epion Therapeutics vs
Trefoil Therapeutics
Trefoil Therapeutics United States

Developing first-in-class investigational medicines for serious corneal diseases and disorders

Venture round
11 employees
Biotechnology, Health Care
View all alternatives

FAQ About Epion Therapeutics

A clinical-stage company developing a minimally-invasive treatment for keratoconus
Epion Therapeutics was founded in 2012.
Epion Therapeutics is headquartered in Burlington, United States.
Epion Therapeutics operates in Biotechnology, Health Care, Health and Wellness, Life Sciences and Pharmaceutical. Its work centres on clinical-stage company, corneal diseases, keratoconus and minimally-invasive treatment.
Epion Therapeutics has approximately 12 employees.
Epion Therapeutics has completed 1 funding round, raising a total of $32.00M. The latest funding stage is Series A.
Top alternatives and competitors to Epion Therapeutics include Avedro, iVeena, Trefoil Therapeutics, Aurion Biotech, Brightstar Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Epion Therapeutics and Avedro are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Epion Therapeutics, https://bouncewatch.com/company/epion-therapeutics, updated 21 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout